Rocket


Overview
Financials
News + Filings
Key Docs
Transactions
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

PureTech Health plc Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
08/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
06/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cover letter from the Company to its shareholders",
"Letter from KPMG to the shareholders of the Company"
06/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/31/2023 4 PureTech Health plc (10% Owner) has filed a Form 4 on GELESIS HOLDINGS, INC.
Txns: Bought convertible notes @ $0.0142, valued at $0
Bought 43,133,803 warrants @ $0.0142, valued at $612.5k
05/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/28/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/28/2023 6-K Quarterly results
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PureTech Health plc PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million"
03/20/2023 6-K Quarterly results
03/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
02/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
12/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PureTech Health plc PureTech Provides End of Year Report on Key Progress"
12/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
11/03/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
10/11/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PureTech Health plc Statement regarding termination of discussions with Nektar Therapeutics PureTech announces that it has mutually agreed with Nektar to terminate discussions regarding a possible business combination. Discussions with Nektar were announced on 7 October 2022, as required by Rule 2 of the UK City Code on Takeovers and Mergers , in response to media speculation. These discussions were early in nature and the required announcement created the impression that discussions were more advanced than they were. Given the early stage of the discussions and the potential for an extended period of uncertainty, these discussions were terminated. This announcement has been made with the consent of Nektar. Notwithstanding the termination of discussions, PureTech remains in an “offer peri...",
"Nektar Therapeutics Rule 2.8 Announcement Further to the announcement made by PureTech Health plc on 7 October 2022, Nektar announces that it has mutually agreed with PureTech to terminate discussions regarding a potential business combination. Important Code notes This is a statement to which Rule 2.8 of the Code applies. As is customary under Rule 2.8 of the Code, Nektar reserves the right to make or participate in an offer for PureTech within the next six months following the date of this announcement: i. with the agreement of the PureTech Board; ii. following the announcement of a firm intention to make an offer for PureTech by or on behalf of a third party; iii. following the announcement by PureTech of a Rule 9 waiver proposal or a reverse takeover ; or iv. where the Takeover Panel h..."
10/07/2022 6-K Quarterly results
10/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
08/30/2022 SC 13D PureTech Health plc reports a 14.7% stake in Akili, Inc.
08/29/2022 3 PureTech Health plc (10% Owner) has filed a Form 3 on Akili, Inc.
08/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"25 August 2022 PureTech Health"
08/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PureTech Health plc"
08/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
07/05/2022 6-K Quarterly results
06/15/2022 6-K Quarterly results
06/03/2022 6-K Quarterly results
05/09/2022 6-K Quarterly results
05/05/2022 6-K Quarterly results
04/26/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PureTech Announces Annual Results for Year Ended December 31, 2021"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy